-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Schedules Biosimilar Biological Product Development Type 2a Meeting With AEON Biopharma Regarding ABP-450

Benzinga·10/01/2025 12:10:30
Listen to the news

- Meeting date aligns with prior guidance -

- FDA to review AEON's analytical development plan and initial data -